TY - JOUR
T1 - Gastric Linitis Plastica
T2 - Clinical Characteristics and Outcomes from the National Cancer Database
AU - Ayub, Adil
AU - Naeem, Buria
AU - Perez, Alexander
AU - Tyler, Douglas
AU - Suzanne Klimberg, V.
N1 - Publisher Copyright:
© 2023 International Institute of Anticancer Research. All rights reserved.
PY - 2023/4
Y1 - 2023/4
N2 - Background/Aim: Gastric linitis plastica (LP) is a rare type of gastric tumor with limited data. We sought to investigate the clinical characteristics, treatment modalities, and outcomes utilizing a national database. Patients and Methods: The National Cancer Database (NCDB) was reviewed for LP of the stomach from 2004 to 2017. Kaplan–Meier analysis and Cox proportional hazards model were utilized to evaluate overall survival and predictors of survival. Results: Out of 222,488 gastric cancer cases, 896 patients with histologically confirmed primary gastric LP were included. Patients were predominantly white (78.5%), female (51.9%) and presented at advanced stage disease (stage 4=69%). A total of 369 (41.2%) patients underwent surgical resection, 520 (58.0%) received chemotherapy and 158 (17.6%) received radiation therapy. The mean OS (overall survival) of the entire cohort was 16.9 months with 1-year and 5-year OS rates of 33% and 5%, respectively. Mean OS for the patients receiving surgery with chemotherapy and/or radiation, surgery alone, chemotherapy and/or radiotherapy alone, and no treatment was 28.4, 17.1, 12.3, and, 8.1 months, respectively (p<0.001). On multivariate cox-regression analysis, advanced-stage disease (stage IV) (p<0.001), no surgical resection (p<0.001), and no receipt of chemotherapy (p<0.001) were associated with increased hazards of death. Over time, the proportion of patients receiving surgical resection (30.7% from 48.3%) and radiation therapy decreased (13.8% from 20.6%) and the use of chemotherapy increased (63.9% from 54.8%). Conclusion: Gastric LP is associated with a poor prognosis. Multimodal therapy including surgical resection and systemic therapy in the neoadjuvant setting seems to provide the best long-term outcomes.
AB - Background/Aim: Gastric linitis plastica (LP) is a rare type of gastric tumor with limited data. We sought to investigate the clinical characteristics, treatment modalities, and outcomes utilizing a national database. Patients and Methods: The National Cancer Database (NCDB) was reviewed for LP of the stomach from 2004 to 2017. Kaplan–Meier analysis and Cox proportional hazards model were utilized to evaluate overall survival and predictors of survival. Results: Out of 222,488 gastric cancer cases, 896 patients with histologically confirmed primary gastric LP were included. Patients were predominantly white (78.5%), female (51.9%) and presented at advanced stage disease (stage 4=69%). A total of 369 (41.2%) patients underwent surgical resection, 520 (58.0%) received chemotherapy and 158 (17.6%) received radiation therapy. The mean OS (overall survival) of the entire cohort was 16.9 months with 1-year and 5-year OS rates of 33% and 5%, respectively. Mean OS for the patients receiving surgery with chemotherapy and/or radiation, surgery alone, chemotherapy and/or radiotherapy alone, and no treatment was 28.4, 17.1, 12.3, and, 8.1 months, respectively (p<0.001). On multivariate cox-regression analysis, advanced-stage disease (stage IV) (p<0.001), no surgical resection (p<0.001), and no receipt of chemotherapy (p<0.001) were associated with increased hazards of death. Over time, the proportion of patients receiving surgical resection (30.7% from 48.3%) and radiation therapy decreased (13.8% from 20.6%) and the use of chemotherapy increased (63.9% from 54.8%). Conclusion: Gastric LP is associated with a poor prognosis. Multimodal therapy including surgical resection and systemic therapy in the neoadjuvant setting seems to provide the best long-term outcomes.
KW - Gastric cancer
KW - gastrectomy
KW - linitis plastica
UR - http://www.scopus.com/inward/record.url?scp=85150958380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150958380&partnerID=8YFLogxK
U2 - 10.21873/anticanres.16303
DO - 10.21873/anticanres.16303
M3 - Article
C2 - 36974782
AN - SCOPUS:85150958380
SN - 0250-7005
VL - 43
SP - 1543
EP - 1548
JO - Anticancer Research
JF - Anticancer Research
IS - 4
ER -